Both in Pharmaceuticals
Celularity vs TransCode Therapeutics
Over the past year CELU returned −52.5% and RNAZ returned −85.1%; their daily moves had a correlation of 0.05.
CELU −52.5% RNAZ −85.1%Growth of $1, one year, split-adjusted
| Metric | CELU | RNAZ |
|---|---|---|
| Price | $0.8171 | $1.57 |
| Market cap | $26.5M | $26.6M |
| Today | +1.82% | −3.68% |
| 1 month | −52.2% | −10.8% |
| 6 months | −14.3% | −80.0% |
| Year to date | −26.4% | −77.0% |
| 1 year | −58.1% | — |
| Revenue growth (YoY) | −5.3% | — |
| Gross margin | 56.8% | — |
| Net margin | 10.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 1.4× | — |
| Net cash | -$37.1M | $7.7M |
| Dividend yield | — | — |
| Volatility (60d) | 223.1% | 75.6% |
| Short % of float | 6.7% | 8.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).